Evelien L J Smits

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2038467/publications.pdf

Version: 2024-02-01

162 papers	6,914 citations	66343 42 h-index	82547 72 g-index

170 all docs	170 docs citations	170 times ranked	9965 citing authors

#	Article	IF	Citations
1	Clinical use of dendritic cells for cancer therapy. Lancet Oncology, The, 2014, 15, e257-e267.	10.7	565
2	Induction of complete and molecular remissions in acute myeloid leukemia by Wilmsâ€™ tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13824-13829.	7.1	341
3	CD56 in the Immune System: More Than a Marker for Cytotoxicity?. Frontiers in Immunology, 2017, 8, 892.	4.8	239
4	The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology, 2020, 60, 41-56.	9.6	226
5	The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. Oncologist, 2008, 13, 859-875.	3.7	192
6	Nonâ€Thermal Plasma as a Unique Delivery System of Shortâ€Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. Advanced Science, 2019, 6, 1802062.	11.2	177
7	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood, 2017, 130, 1713-1721.	1.4	170
8	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials. , 2016, 158, 24-40.		158
9	CD70: An emerging target in cancer immunotherapy. , 2015, 155, 1-10.		136
10	Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs. , 2015, 146, 120-131.		134
11	Natural killer cell immune escape in acute myeloid leukemia. Leukemia, 2012, 26, 2019-2026.	7.2	131
12	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacological Reviews, 2015, 67, 731-753.	16.0	129
13	Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections. Journal of Clinical Investigation, 2017, 127, 3543-3556.	8.2	125
14	Anti-cancer capacity of plasma-treated PBS: effect of chemical composition on cancer cell cytotoxicity. Scientific Reports, 2017, 7, 16478.	3.3	103
15	Interferon-Î± in acute myeloid leukemia: an old drug revisited. Leukemia, 2011, 25, 739-748.	7.2	101
16	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. Journal of Hematology and Oncology, 2016, 9, 101.	17.0	96
17	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.9	93
18	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Aids, 2012, 26, F1-F12.	2.2	88

#	Article	IF	Citations
19	Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Frontiers in Immunology, 2018, 9, 394.	4.8	84
20	Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment. Cancers, 2019, 11, 1287.	3.7	81
21	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012, 120, 3936-3944.	1.4	80
22	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers, 2019, 11, 1597.	3.7	77
23	NK Cells: Key to Success of DC-Based Cancer Vaccines?. Oncologist, 2012, 17, 1256-1270.	3.7	76
24	Immunosuppression induced by immature dendritic cells is mediated by TGFâ€Î²2/ILâ€10 doubleâ€positive CD4⁺ regulatory T cells. Journal of Cellular and Molecular Medicine, 2008, 12, 690-700.	3.6	75
25	Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. Journal of Translational Medicine, 2009, 7, 109.	4.4	74
26	Reduction of Human Glioblastoma Spheroids Using Cold Atmospheric Plasma: The Combined Effect of Short- and Long-Lived Reactive Species. Cancers, 2018, 10, 394.	3.7	69
27	Dendritic Cell-Based Cancer Gene Therapy. Human Gene Therapy, 2009, 20, 1106-1118.	2.7	68
28	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. OncoImmunology, 2017, 6, e1261241.	4.6	67
29	Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biology, 2021, 42, 101949.	9.0	63
30	Tumoricidal activity of human dendritic cells. Trends in Immunology, 2014, 35, 38-46.	6.8	62
31	SARS-CoV-2 and cancer: Are they really partners in crime?. Cancer Treatment Reviews, 2020, 89, 102068.	7.7	60
32	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget, 2017, 8, 56968-56979.	1.8	59
33	Cold atmospheric plasma treatment of melanoma and glioblastoma cancer cells. Plasma Processes and Polymers, 2016, 13, 1195-1205.	3.0	57
34	RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2019, 133, 85-91.	4.4	57
35	RNA-based gene transfer for adult stem cells and T cells. Leukemia, 2004, 18, 1898-1902.	7.2	56
36	Modifying the Tumour Microenvironment: Challenges and Future Perspectives for Anticancer Plasma Treatments. Cancers, 2019, 11, 1920.	3.7	56

#	Article	IF	Citations
37	Immune Checkpoint Modulation in Colorectal Cancer: Whatâ€™s New and What to Expect. Journal of Immunology Research, 2015, 2015, 1-16.	2.2	54
38	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
39	The CD70-CD27 axis in oncology: the new kids on the block. Journal of Experimental and Clinical Cancer Research, 2022, 41, 12.	8.6	53
40	The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunology, Immunotherapy, 2010, 59, 35-46.	4.2	51
41	Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy, 2012, 14, 647-656.	0.7	49
42	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PLoS ONE, 2012, 7, e51851.	2.5	48
43	Immunotherapy of Acute Myeloid Leukemia: Current Approaches. Oncologist, 2009, 14, 240-252.	3.7	47
44	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. PLoS ONE, 2015, 10, e0123340.	2.5	47
45	<scp>CD</scp>70 and <scp>PD</scp>â€Ł1 in anaplastic thyroid cancerÂâ€“Âpromising targets for immunotherapy. Histopathology, 2017, 71, 357-365.	2.9	47
46	Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders. Vaccine, 2018, 36, 6282-6289.	3.8	47
47	Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. Oncotarget, 2015, 6, 13462-13475.	1.8	45
48	Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia, 2007, 21, 1691-1699.	7.2	43
49	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1Î± and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. Cancers, 2018, 10, 126.	3.7	43
50	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget, 2017, 8, 89722-89735.	1.8	43
51	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treatment Reviews, 2015, 41, 914-924.	7.7	41
52	Oxidative damage to hyaluronanâ€“CD44 interactions as an underlying mechanism of action of oxidative stress-inducing cancer therapy. Redox Biology, 2021, 43, 101968.	9.0	41
53	Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. International Journal of Cancer, 2004, 108, 258-261.	5.1	39
54	Transpresentation of interleukin-15 by IL-15/IL-15RÎ± mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget, 2015, 6, 44123-44133.	1.8	39

#	Article	IF	Citations
55	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. OncoImmunology, 2018, 7, e1407899.	4.6	38
56	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. Frontiers in Immunology, 2018, 9, 658.	4.8	38
57	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Cancers, 2021, 13, 987.	3.7	38
58	Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. , 2018, 189, 31-44.		37
59	Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. Cells, 2020, 9, 1474.	4.1	37
60	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNAâ€“Transfected Dendritic Cells. Transplantation, 2015, 99, 120-127.	1.0	36
61	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. Cancer Immunology Research, 2017, 5, 710-715.	3.4	36
62	Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects. Antioxidants, 2020, 9, 1188.	5.1	36
63	Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. Cells, 2021, 10, 2936.	4.1	35
64	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. Immunotherapy, 2011, 3, 1203-1222.	2.0	34
65	Interferon Î± may be back on track to treat acute myeloid leukemia. OncoImmunology, 2013, 2, e23619.	4.6	33
66	Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. OncoImmunology, 2018, 7, e1440167.	4.6	33
67	Exploring the Impact of Exposure to Primary Varicella in Children on Varicella-Zoster Virus Immunity of Parents. Viral Immunology, 2011, 24, 151-157.	1.3	32
68	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. PLoS ONE, 2011, 6, e20952.	2.5	31
69	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. Hum Vaccin, 2011, 7, 579-584.	2.4	30
70	Interleukin-15: New kid on the block for antitumor combination therapy. Cytokine and Growth Factor Reviews, 2015, 26, 15-24.	7.2	30
71	Vaccine and immune cell therapy in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S1602-S1614.	1.4	30
72	CD56 marks human dendritic cell subsets with cytotoxic potential. OncoImmunology, 2013, 2, e23037.	4.6	29

#	Article	IF	Citations
73	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. Frontiers in Immunology, 2018, 9, 2503.	4.8	29
74	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2013, 9, 1956-1961.	3.3	28
75	Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox. Scientific Reports, 2017, 7, 1077.	3.3	28
76	Cold Atmospheric Plasma Increases Temozolomide Sensitivity of Three-Dimensional Glioblastoma Spheroids via Oxidative Stress-Mediated DNA Damage. Cancers, 2021, 13, 1780.	3.7	28
77	Engineering monocyte-derived dendritic cells to secrete interferon-Î± enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunology, Immunotherapy, 2015, 64, 831-842.	4.2	27
78	NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics, 2021, 11, 478.	2.6	27
79	Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunology, Immunotherapy, 2011, 60, 757-769.	4.2	26
80	Influence of Frequent Infectious Exposures on General and Varicella-Zoster Virus-Specific Immune Responses in Pediatricians. Vaccine Journal, 2014, 21, 417-426.	3.1	26
81	Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. OncoImmunology, 2015, 4, e1023973.	4.6	26
82	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. OncoImmunology, 2016, 5, e1227902.	4.6	26
83	Novel combination immunotherapy for pancreatic cancer: potent antiâ€tumor effects with CD40 agonist and interleukinâ€15 treatment. Clinical and Translational Immunology, 2020, 9, e1165.	3.8	26
84	Oxidation of Innate Immune Checkpoint CD47 on Cancer Cells with Non-Thermal Plasma. Cancers, 2021, 13, 579.	3.7	26
85	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Science Advances, 2021, 7, .	10.3	26
86	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. Expert Review of Anticancer Therapy, 2014, 14, 1173-1187.	2.4	25
87	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. British Journal of Cancer, 2020, 123, 752-761.	6.4	25
88	Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?. Cancers, 2021, 13, 360.	3.7	25
89	Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death. Free Radical Biology and Medicine, 2021, 166, 187-200.	2.9	24
90	Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. Cancers, 2019, 11, 1611.	3.7	23

#	Article	IF	Citations
91	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. International Journal of Molecular Sciences, 2019, 20, 2183.	4.1	22
92	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. , 2022, 236, 108107.		22
93	Cold Atmospheric Plasma Treatment for Pancreatic Cancerâ€"The Importance of Pancreatic Stellate Cells. Cancers, 2020, 12, 2782.	3.7	20
94	IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation. , 2017, 170, 73-79.		19
95	Memory CD4+ T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus. Genes and Immunity, 2019, 20, 255-260.	4.1	19
96	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers, 2020, 12, 863.	3.7	18
97	The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. Cancers, 2021, 13, 282.	3.7	18
98	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget, 2017, 8, 13652-13665.	1.8	18
99	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Oncotarget, 2016, 7, 73960-73970.	1.8	17
100	HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV â€positive tumour cells. Journal of Cellular and Molecular Medicine, 2014, 18, 1372-1380.	3.6	16
101	The role of the common gamma-chain family cytokines in Î³Î´ T cell-based anti-cancer immunotherapy. Cytokine and Growth Factor Reviews, 2018, 41, 54-64.	7.2	16
102	Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. Cancer Immunology, Immunotherapy, 2019, 68, 1573-1583.	4.2	15
103	Cold Atmospheric Plasma Does Not Affect Stellate Cells Phenotype in Pancreatic Cancer Tissue in Ovo. International Journal of Molecular Sciences, 2022, 23, 1954.	4.1	15
104	The effect of local <scp>nonâ€thermal</scp> plasma therapy on the <scp>cancerâ€immunity</scp> cycle in a melanoma mouse model. Bioengineering and Translational Medicine, 2022, 7, .	7.1	15
105	Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 2021, 148, 328-339.	2.8	14
106	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	2.5	13
107	BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?. Vaccines, 2018, 6, 65.	4.4	13
108	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. Cancers, 2019, 11, 1396.	3.7	13

#	Article	IF	Citations
109	Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 3853-3866.	1.8	13
110	Quantification of IFN-Î³ produced by human purified NK cells following tumor cell stimulation: Comparison of three IFN-Î³ assays. Journal of Immunological Methods, 2009, 350, 89-96.	1.4	12
111	The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. Journal of Immunological Methods, 2010, 357, 51-54.	1.4	12
112	Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-Î³ secretion by human NK cells. Leukemia Research, 2009, 33, 539-546.	0.8	11
113	Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use. Journal of Immunology Research, 2017, 2017, 1-8.	2.2	11
114	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. International Journal of Molecular Sciences, 2019, 20, 4182.	4.1	11
115	Preexisting memory CD4 T cells in naÃ¯ve individuals confer robust immunity upon hepatitis B vaccination. ELife, 2022, 11, .	6.0	11
116	Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium. Leukemia Research, 2016, 46, 26-29.	0.8	10
117	Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.. Journal of Clinical Oncology, 2014, 32, 7583-7583.	1.6	10
118	Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens. Clinical and Experimental Immunology, 2018, 194, 192-204.	2.6	9
119	Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. Oncotarget, 2017, 8, 74058-74067.	1.8	9
120	Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?. Biomedicines, 2022, 10, 823.	3.2	9
121	Identification of a Wilmsâ€™ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes. Leukemia, 2013, 27, 748-750.	7.2	8
122	Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity. Immunogenetics, 2018, 70, 363-372.	2.4	8
123	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. International Journal of Molecular Sciences, 2021, 22, 1807.	4.1	8
124	Toward defining plasma treatment dose: The role of plasma treatment energy of pulsedâ€dielectric barrier discharge in dictating in vitro biological responses. Plasma Processes and Polymers, 2022, 19, e2100151.	3.0	8
125	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. Cancers, 2019, 11, 1029.	3.7	7
126	Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer. Current Colorectal Cancer Reports, 2013, 9, 380-390.	0.5	6

#	Article	IF	Citations
127	Generation and Cryopreservation of Clinical Grade Wilmsâ€™ Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. Methods in Molecular Biology, 2016, 1393, 27-35.	0.9	6
128	Critical Evaluation of the Interaction of Reactive Oxygen and Nitrogen Species with Blood to Inform the Clinical Translation of Nonthermal Plasma Therapy. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-10.	4.0	6
129	WT1-Targeted Dendritic Cell Vaccination as A Post-Remission Treatment to Prevent Full Relapse In Acute Myeloid Leukemia. Blood, 2010, 116, 16-16.	1.4	6
130	Prevention Of Relapse In Acute Myeloid Leukemia By Dendritic Cell Vaccination: Report on a Phase II Study With 29 Patients. Blood, 2013, 122, 236-236.	1.4	6
131	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. Critical Reviews in Oncology/Hematology, 2021, 157, 103190.	4.4	5
132	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. Blood, 2014, 124, 310-310.	1.4	5
133	NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects. Pathology and Oncology Research, 0, 28, .	1.9	5
134	Viral infections following allogeneic stem cell transplantation: how to cure the cure?. Leukemia and Lymphoma, 2010, 51, 965-966.	1.3	4
135	Creating a robust framework for the analysis of cryopreserved samples in quantitative immunological experiments. Journal of Immunological Methods, 2013, 392, 63-67.	1.4	4
136	Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity. Mediators of Inflammation, 2016, 2016, 1-2.	3.0	4
137	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines, 2022, 10, 673.	3.2	4
138	New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 2020, 69, 867-877.	4.2	3
139	Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients. Blood, 2014, 124, 1322-1322.	1.4	3
140	Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy. Biomedicines, 2022, 10, 1074.	3.2	3
141	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready â€˜N Able to Improve Clinical Outcome?. Cancers, 2020, 12, 299.	3.7	2
142	Abstract 958: Blocking CD70+ cancer associated fibroblasts: Are we paving the way towards immunotherapy in colorectal cancer. Cancer Research, 2017, 77, 958-958.	0.9	2
143	Electroporation of Dicer-Substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms' Tumor 1 (WT1)-Specific TCR-Redirected Cytotoxic T Cells. Blood, 2016, 128, 813-813.	1.4	2
144	Sampling Site Matters When Counting Lymphocyte Subpopulations. PLoS ONE, 2012, 7, e41405.	2.5	2

#	Article	IF	Citations
145	Abstract B137: Preclinical evaluation of a Wilmsâ€™ tumor protein 1-targeted interleukin-15 dendritic cell vaccine: T-cell activity and batch production. Cancer Immunology Research, 2019, 7, B137-B137.	3.4	2
146	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Frontiers in Immunology, 2022, 13, 734256.	4.8	2
147	New Implications of Patientsâ€™ Sex in Todayâ€™s Lung Cancer Management. Cancers, 2022, 14, 3399.	3.7	1
148	Dendritic Cells in Hematopoietic Stem Cell Transplantation. , 0, , .		0
149	Interleukin-15 and Interleukin-15 Receptor Î± mRNA-engineered Dendritic Cells as Promising Candidates for Dendritic Cell-based Vaccination in Cancer Immunotherapy. Journal of Cancer Science & Therapy, 2016, 08, .	1.7	0
150	OA02.07 Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S249-S250.	1.1	0
151	Combining top-ranked immunotherapeutics in lung cancer. Lancet Oncology, The, 2018, 19, 592-594.	10.7	0
152	RNA Electroporation as a New Gene Transfer Method in Hematopoietic Progenitor Cells, Mesenchymal Cells and Activated T-Cells.. Blood, 2004, 104, 5269-5269.	1.4	0
153	Loading of Acute Myeloid Leukemia Cells with Poly(I:C) by Electroporation. Methods in Molecular Biology, 2014, 1139, 233-241.	0.9	0
154	Abstract 4981: Cisplatin and anti-CD70 therapy: Ideal partners in crime against NSCLC. , 2016, , .		0
155	Abstract 258: Is P53 the up-and-coming predictive biomarker for volasertib treatment in NSCLC. , 2016, , .		0
156	Abstract 3715A: Effusions of mesothelioma patients: What's in it for immunotherapy. , 2017, , .		0
157	Abstract B192: CD56 participation in immune effector cell activation and tumor cell eradication: A role for interleukin-15. , 2019, , .		0
158	Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer: Preliminary results.. Journal of Clinical Oncology, 2020, 38, e18028-e18028.	1.6	0
159	Abstract 3371: Role of the epidermal growth factor receptor expression and internalization in cetuximab-induced antibody-dependent cellular cytotoxicity in head and neck squamous cell carcinoma. , 2020, , .		0
160	Abstract 2962: Molecular mechanisms underlying the sensitizing effect of mutant p53 protein expression for Auranofin treatment of NSCLC and PDAC cells. , 2020, , .		0
161	Abstract 2414: Immunogenic properties of chemotherapeutic agents in the treatment of non-small cell lung cancer. , 2020, , .		0
162	453â€…Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment. , 2020, , .		0